Marksans Pharma (MARKSANS) Q4 04/05 earnings summary

Executive summary

• FY05 consolidated sales rose to Rs 2,545.32 million from Rs 1,388.27 million; net profit after tax reached Rs 205.59 million from Rs 82.57 million.

• Growth reflected stronger bulk drugs and formulations, expanded manufacturing capacity, and the amalgamation effective 1 April 2004.

Financial highlights

• Consolidated profit before tax was Rs 250.68 million versus Rs 102.69 million; net profit after tax was Rs 205.59 million versus Rs 82.57 million.

• Turnover increased 85.14% YoY; reported operating profit before depreciation, tax and non-recurring items was Rs 318.08 million versus Rs 164.01 million.

• Consolidated cost of sales rose to 75.07% of sales from 70.31%, citing lower bulk-active realizations and domestic competition.

• Interest and financial charges increased to Rs 119.15 million from Rs 107.55 million; R&D expense was Rs 46.73 million.

Outlook and guidance

• Outlook described as encouraging, supported by R&D, bulk actives, formulations, regulated-market expansion, and customized entry into new global markets.

• Plans emphasized therapeutic-area expansion, five new marketing divisions, manufacturing upgrades, regulatory readiness, alliances, and investment in IPR and drug-delivery systems.